The Venture Codex Logo

The Venture Codex

Overview

Transformative medicines using CRISPR/Cas9 gene-editing technology.

Founded

2013

Deals · 12mo

0

Stage focus

Series A

Geographic focus

United States

Sector focus

Biopharma
Biotechnology
Genetics
Medical

Investment portfolio

1rounds
NAMEDATESIZE
Exsilio Therapeutics
Jun 2024Participated
$82 MSeries A
Exsilio Therapeutics
Jun 2024Participated
$82 MSeries A
1
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

CRISPR Therapeutics: 1 funding rounds are recorded in the selected participation categories.All available history.
CRISPR Therapeutics: 1 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A01

Monthly Deal Activity

CRISPR Therapeutics: 1 deals are recorded across 29 months.All available history.
CRISPR Therapeutics: 1 deals are recorded across 29 months. All available history
MonthDeals
Jun '241
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

CRISPR Therapeutics: Health & Life Sciences is the largest displayed sector by deal count (1 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

CRISPR Therapeutics: Health & Life Sciences is the largest displayed sector by deal count (1 deals). All available history
SectorDeals
Health & Life Sciences1

Deal Size Distribution

CRISPR Therapeutics: 1 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

CRISPR Therapeutics: 1 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M0
$25M-$50M0
$50M-$100M1
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

CRISPR Therapeutics: United States has the largest recorded deal count among the displayed regions (1 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

CRISPR Therapeutics: United States has the largest recorded deal count among the displayed regions (1 deals). All available history
RegionDeals
United States1
CRISPR Therapeutics: 9 co-investors are shown, with Arc Ventures sharing 1 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

CRISPR Therapeutics: 9 co-investors are shown, with Arc Ventures sharing 1 recorded deals. All available history
Co-investorShared deals
Arc Ventures1
Deep Insight1
Delos Capital1
Innovation Endeavors1
Insight Partners1
Invus1
J.P. Morgan1
Novartis1
OrbiMed1

Investment Strategy

CRISPR Therapeutics: Led accounts for 0% and participating for 100% of round participation.All available history.
CRISPR Therapeutics: Led accounts for 0% and participating for 100% of round participation. All available history
CategoryDeals (count)Share (%)
Led00%
Participating1100%
CRISPR Therapeutics: Single-lead accounts for 0% and co-led for 0% of lead dynamics.All available history.
CRISPR Therapeutics: Single-lead accounts for 0% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led00%

Lead dynamics requires at least one led deal in this range

Team

Craig Mello

Scientific Founders

Daniel Anderson

Scientific Founders

Doug Treco

Director

Emmanuelle Charpentier

Co-Founder & Scientific Advisory Board Member

Matthew Porteus

Scientific Founders

Naimish Patel

Chief Medical Officer

Phuong Khanh Morrow

chief medical officer

Raju Prasad

Chief Financial Officer

Stephen Kennedy

Head Of Technical Operations